Exelixis develops and commercializes medicines, with a major focus on cancer. To understand the company, keep three records separate: approved product uses, investigational programs and the business that funds them. This guide shows where to verify each record and how to read a new announcement. Clinical scope below concerns the United States and was checked on September 16, 2026.
Begin with the exact medicine and indication
The company's medicines page separates Exelixis products from partnered programs and links to prescribing information. CABOMETYX and COMETRIQ both contain cabozantinib, but have different formulations and labeled uses. COTELLIC (cobimetinib) is listed as a partnered program; commercial rights and responsibilities should be checked by product and country.
| Name | What to establish | Primary reference |
|---|---|---|
| CABOMETYX | Cabozantinib tablets; specified uses in kidney, liver, differentiated thyroid and neuroendocrine cancers, with indication-specific conditions. | Full U.S. prescribing information (PDF) |
| COMETRIQ | Cabozantinib capsules; progressive, metastatic medullary thyroid cancer. | Full U.S. prescribing information (PDF) |
| Zanzalintinib / XL092 | An investigational program with multiple trials; record the proposed regimen and population separately. | Company clinical-trials and pipeline page |
Read the indication section for the cancer type, stage, prior treatment, age and any combination partner. CABOMETYX's label explicitly says not to substitute it with cabozantinib capsules. Treatment selection and monitoring require the treating oncology team and the complete current label; the table is a reading guide.
Use a dated approval as an evidence example
On March 26, 2025, FDA approved an additional CABOMETYX use for adults and patients aged 12 or older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors. FDA describes the CABINET trial and its progression-free-survival endpoint.
Notice how much information is lost if this becomes “approved for cancer.” A usable claim preserves the disease, treatment setting and population. An additional indication for an existing drug also differs from the first approval of a new molecule. For a headline, record both the decision date and the exact use it concerns.
Read the pipeline as a set of questions under study
As of this guide's September 16, 2026 check, Exelixis's August 5, 2026 corporate update in its Form 8-K (PDF) described ongoing FDA review of zanzalintinib with atezolizumab for previously treated metastatic colorectal cancer. The reported target action date was December 3, 2026. Acceptance for review and a target date describe a review process; a final decision still needs its own record.
The same update distinguishes the positive overall-survival result in the full intention-to-treat population of STELLAR-303 from a later non-statistically-significant result in the subgroup without liver metastases. This is a useful reason to preserve the population and endpoint when comparing announcements about one trial.
Open STELLAR-303, NCT05425940 and match the intervention, comparator, eligibility and planned outcomes. XL092 is the development code used for zanzalintinib. Trial records are supplied by responsible parties and have update histories; a registry entry helps identify the study, while results and regulatory review answer different questions.
A repeatable check for an Exelixis announcement
- Copy the date, exact molecule, development code, regimen and cancer setting into a note.
- Find the trial identifier and check that the record matches the announcement.
- Identify the primary endpoint, analysis population, comparator and follow-up period.
- Read benefit and adverse-event results together, including uncertainty and treatment discontinuation.
- Check regulatory documents for an approved use, or record the unresolved review step.
- Separate measured results from company forecasts, planned studies and possible commercial uses.
Connect the science to the company record
Use Exelixis annual reports for the business description, risks and audited financial statements, and read subsequent quarterly filings for changes. Distinguish product sales, royalties and collaboration payments: each reflects a different economic relationship. A global medicine can have different commercialization partners in different territories.
Check how dependent the business is on particular products, which programs require further spending, and which patent, competition or development risks management identifies. Scientific promise, an approved indication and a sustainable business each require their own evidence. The biotech-stocks guide explains financial comparisons and fictional runway calculations in more detail.
Download the Exelixis evidence log for a reusable record of products, trial claims and unresolved questions. Recheck it when a label changes, a trial reports results or a regulatory decision arrives. For an individual treatment question, bring the relevant label or trial record to the oncology team; for company research, keep clinical findings separate from an investment conclusion.